Please use this identifier to cite or link to this item:
Title: Advances in immunosuppression for kidney transplantation: new strategies for preserving kidney function and reducing cardiovascular risk
Other Titles: Avances en la inmunosupresión para el trasplante renal. Nuevas estrategias para preservar la función renal y reducir el riesgo cardiovascular
Author: Bestard Matamoros, Oriol
Campistol Plana, Josep M.
Morales, José M.
Sánchez-Fructuoso, A.
Cabello, Mercedes
Cabello, Virginia
Pallardó, L.M.
Grinyo Boira, Josep M.
Keywords: Trasplantament renal
Factors de risc en les malalties
Kidney transplantation
Immunosupressive agents
Risk factors in diseases
Issue Date: 1-Jan-2012
Publisher: Elsevier España
Abstract: The development of new immunosuppressants for renal transplantation is aimed not only at improving short-term outcomes, but also at achieving better safety, cardiovascular, and metabolic profiles and at decreasing nephrotoxicity. Belatacept is a fusion protein that inhibits T cell activation by binding to CD80 and CD86 antigens. Clinical trials, particularly the BENEFIT and BENEFIT-EXT studies, have shown that belatacept preserves function and structure in renal grafts. The effects of belatacept provide long-term, sustained results, and the safety and efficacy of this drug have been demonstrated in cases of renal transplantation from expanded criteria donors. Compared to calcineurin inhibitors, belatacept is associated with a lower incidence of chronic allograft nephropathy and a more favourable cardiovascular and metabolic profile.
Note: Reproducció del document publicat a:
It is part of: Nefrología, 2012, vol. 32, num. 3, p. 374-384
Related resource:
ISSN: 0211-6995
Appears in Collections:Articles publicats en revistes (Ciències Clíniques)

Files in This Item:
File Description SizeFormat 
621688.pdf90.95 kBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons